









Markets
/
Stocks
/
nasdaq-alec
/

Alector Inc

ALEC

1.300USD

+0.045+3.59%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

131.58MMarket Cap

LossP/E TTM



Alector Inc

1.300

+0.045+3.59%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alector Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alector Inc's Score

Industry at a Glance

Industry Ranking

161 / 407

Overall Ranking

289 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Hold

Current Rating

2.200

Target Price

+75.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alector Inc Highlights

StrengthsRisks

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Overvalued

The company’s latest PE is -1.12, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 77.85M shares, decreasing 21.58% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 90.75K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.92.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 5.97, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 7.87M, representing a year-over-year decrease of 47.80%, while its net profit experienced a year-over-year decrease of 21.08%.

Score

Industry at a Glance

Previous score

5.97

Change



Financials

4.18

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.79

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Alector Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.04, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -1.12, which is -35.80% below the recent high of -0.72 and -442.43% above the recent low of -6.09.

Score

Industry at a Glance

Previous score

7.04

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 161/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 5.78, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Alector Inc is 1.50, with a high of 5.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

5.78

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Hold

Current Rating

2.200

Target Price

+75.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Alector Inc

ALEC

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.44, which is lower than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 2.73 and the support level at 0.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.37

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.158

Sell

RSI(14)

26.321

Sell

STOCH(KDJ)(9,3,3)

12.221

Oversold

ATR(14)

0.274

Low Volatility

CCI(14)

-67.201

Neutral

Williams %R

96.217

Oversold

TRIX(12,20)

-2.845

Sell

StochRSI(14)

64.489

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.357

Sell

MA10

1.436

Sell

MA20

2.123

Sell

MA50

2.615

Sell

MA100

2.186

Sell

MA200

1.785

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 76.91%, representing a quarter-over-quarter decrease of 16.67%. The largest institutional shareholder is The Vanguard, holding a total of 5.99M shares, representing 5.92% of shares outstanding, with 3.47% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

15.00M

+4.23%

Polaris Venture Partners

9.85M

BlackRock Institutional Trust Company, N.A.

6.19M

-3.57%

The Vanguard Group, Inc.

Star Investors

5.99M

-1.08%

Rosenthal (Arnon)

5.53M

-0.92%

T. Rowe Price Associates, Inc.

Star Investors

4.83M

+652.19%

Merck & Co Inc

3.55M

Acadian Asset Management LLC

2.17M

+50.65%

Eversept Partners, LP

1.99M

+221.67%

Geode Capital Management, L.L.C.

1.98M

+1.02%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.22, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.